Robins Kaplan Named Top Firm for Hatch-Waxman Litigation

Four Partners Named Life Science Stars

October 14, 2022

Robins Kaplan LLP is pleased to announce that LMG Life Sciences has recommended the firm as a top Hatch-Waxman patent litigation firm nationwide for generic pharmaceutical companies. In addition, Jake Holdreith, Jeffrey Hovden, Oren Langer, and Ronald Schutz have been named “Life Science Stars.”

  • Jake Holdreith is a member of the firm’s Executive Board and the leader of the firm’s life sciences group. He has tried jury cases to multi-million-dollar verdicts and resolved complex cases at all stages of litigation. He is a skilled and creative strategist and business counselor who can cut to the heart of a matter in the boardroom and the courtroom. Based on his accomplishments, Holdreith was recently named Hatch-Waxman Litigator of the Year – Generic by LMG Life Sciences. He is ranked in the areas of General Patent Litigation, Patent Strategy & Management, and Hatch-Waxman Patent Litigation.
  • Jeff Hovden practices in the area of patent litigation, with a focus on generic pharmaceutical patent cases under the Hatch-Waxman Act and within the biotechnology industry. He has litigated numerous patent infringement and invalidity actions, including many cases involving top-selling worldwide prescription drugs for both generic and name-brand clients. Hovden routinely advises clients on their intellectual property portfolios and has extensive experience with the Food, Drug, and Cosmetic Act's drug-approval provisions and their attendant regulations. He is ranked in the area of Hatch-Waxman Litigation.
  • Oren Langer is Managing Partner of the firm’s New York office. He focuses his practice on intellectual property and technology litigation. His experience spans various industries, including pharmaceuticals (under the Hatch-Waxman Act regulatory framework), chemicals, telecommunications, video gaming, and retail services. Langer also advises clients on licensing negotiations and campaigns, and monetizing intellectual property in anticipation of prospective mergers or acquisitions. He is ranked in the area of Hatch-Waxman Litigation.
  • Ronald Schutz is chair of the firm’s Executive Board. He is a fellow of the American College of Trial Lawyers and has been recognized by many legal organizations and publications as one of the top lawyers in the country, including The National Law Journal, which named him one of the “Top 10 Winning Litigators in the United States.” Schutz has won a nine-figure and multiple eight-figure jury verdicts, and has secured victories against behemoths such as Apple, Clear Channel, Sony, and Canon. He is ranked in the areas of General Patent Litigation and Hatch-Waxman Litigation.

Jake M. Holdreith

Partner

Member of Executive Board

Oren D. Langer

Partner

Managing Partner, New York Office

Ronald J. Schutz

Partner

Chair of Executive Board

Related Publications

Third Quarter
ANDA Approvals
GENERICally Speaking Hatch Waxman Bulletin
Third Quarter
ANDA Litigation Settlements
GENERICally Speaking Hatch Waxman Bulletin
Third Quarter
Generic Launches
GENERICally Speaking Hatch Waxman Bulletin
Third Quarter
New ANDA Cases
GENERICally Speaking Hatch Waxman Bulletin
September 27, 2022
In re Entresto (Sacubitril/Valsartan) Patent Litigation
GENERICally Speaking Hatch Waxman Bulletin
Back to Top